MX2021005535A - Compuestos antibióticos, métodos de fabricacion de los mismos, composiciones farmacéuticas contienendo los mismos y usos de los mismos. - Google Patents

Compuestos antibióticos, métodos de fabricacion de los mismos, composiciones farmacéuticas contienendo los mismos y usos de los mismos.

Info

Publication number
MX2021005535A
MX2021005535A MX2021005535A MX2021005535A MX2021005535A MX 2021005535 A MX2021005535 A MX 2021005535A MX 2021005535 A MX2021005535 A MX 2021005535A MX 2021005535 A MX2021005535 A MX 2021005535A MX 2021005535 A MX2021005535 A MX 2021005535A
Authority
MX
Mexico
Prior art keywords
same
manufacturing
methods
pharmaceutical compositions
compositions containing
Prior art date
Application number
MX2021005535A
Other languages
English (en)
Inventor
Vincent Gerusz
Vasileios Tatsis
Mihiro Sunose
Juan Bravo
Terry Finn
Danig Pohin
Pierre-Michel Regenass
Original Assignee
Debiopharm Int Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debiopharm Int Sa filed Critical Debiopharm Int Sa
Publication of MX2021005535A publication Critical patent/MX2021005535A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/499—Spiro-condensed pyrazines or piperazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Abstract

La presente invención proporciona compuestos de la estructura general (ver Fórmula) que son adecuados como compuestos antibióticos para el tratamiento de infecciones por N. gonorrhoeae e infecciones relacionadas.
MX2021005535A 2018-11-12 2019-11-11 Compuestos antibióticos, métodos de fabricacion de los mismos, composiciones farmacéuticas contienendo los mismos y usos de los mismos. MX2021005535A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18205619 2018-11-12
EP18213016 2018-12-17
PCT/EP2019/080903 WO2020099341A1 (en) 2018-11-12 2019-11-11 Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof

Publications (1)

Publication Number Publication Date
MX2021005535A true MX2021005535A (es) 2021-09-08

Family

ID=68610175

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021005535A MX2021005535A (es) 2018-11-12 2019-11-11 Compuestos antibióticos, métodos de fabricacion de los mismos, composiciones farmacéuticas contienendo los mismos y usos de los mismos.

Country Status (15)

Country Link
US (1) US20230035837A1 (es)
EP (1) EP3880675A1 (es)
JP (1) JP2022506957A (es)
KR (1) KR20210093292A (es)
CN (1) CN113272302A (es)
AU (1) AU2019380568A1 (es)
BR (1) BR112021009106A2 (es)
CA (1) CA3119390A1 (es)
CL (2) CL2021001244A1 (es)
IL (1) IL282950A (es)
MX (1) MX2021005535A (es)
PH (1) PH12021551058A1 (es)
SG (1) SG11202104863RA (es)
TN (1) TN2021000092A1 (es)
WO (1) WO2020099341A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022187329A1 (en) * 2021-03-03 2022-09-09 The Board Of Trustees Of The University Of Illinois Fabi inhibitors for gram-negative pathogens
CA3223459A1 (en) 2021-06-23 2022-12-29 Vincent Gerusz Novel compounds and their use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
PE20010635A1 (es) 1999-10-08 2001-08-15 Smithkline Beecham Corp Inhibidores de fab i utiles para el tratamiento de infecciones bacterianas
DE60230934D1 (de) 2001-04-06 2009-03-05 Affinium Pharm Inc Fab-i-inhibitoren
CA2568914C (en) 2004-06-04 2013-09-24 Affinium Pharmaceuticals, Inc. Therapeutic agents, and methods of making and using the same
US20090156578A1 (en) 2005-12-05 2009-06-18 PAULS Henry 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents
CN101415701A (zh) * 2005-12-05 2009-04-22 Affinium医药公司 作为fabi抑制剂的杂环丙烯酰胺化合物和抗菌剂
US7601716B2 (en) 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
EP2687533B1 (en) * 2006-07-20 2017-07-19 Debiopharm International SA Acrylamide derivatives as FAB I inhibitors
EP2125802A4 (en) 2007-02-16 2014-08-20 Debiopharm Int Sa SALTS, PRODRUGS AND POLYMORPHES OF FAB I INHIBITORS
JO3611B1 (ar) * 2011-08-10 2020-08-27 Janssen Sciences Ireland Uc سايكلو بنتا (سي (بيرول 4,3 ثاني هيدرو 1 hمستبدله [8,1] نافثيريدينونات مضادة للجراثيم
CA2849057C (en) 2011-09-19 2021-05-11 Vitas Pharma Research Pvt Ltd Heterocyclic compounds as inhibitors of fatty acid biosynthesis for bacterial infections
EP2785715A1 (en) 2011-12-02 2014-10-08 Aurigene Discovery Technologies Limited Substituted pyridine derivatives as fabi inhibitors
PL2861608T3 (pl) 2012-06-19 2019-09-30 Debiopharm International Sa Pochodne prolekowe (e)-n-metylo-n-((3-metylobenzofuran-2-ylo)metylo)-3-(7-okso-5,6,7,8-tetrahydro-1,8-naftyrydyn-3-ylo)akryloamidu
EP2882738B1 (en) * 2012-08-10 2017-05-31 Janssen Sciences Ireland UC New antibacterial compounds
SG11201602070TA (en) 2013-09-30 2016-04-28 Beijing Synercare Pharma Tech Co Ltd Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease

Also Published As

Publication number Publication date
CN113272302A (zh) 2021-08-17
SG11202104863RA (en) 2021-06-29
KR20210093292A (ko) 2021-07-27
JP2022506957A (ja) 2022-01-17
TN2021000092A1 (en) 2023-01-05
CA3119390A1 (en) 2020-05-22
CL2022003703A1 (es) 2023-06-09
AU2019380568A1 (en) 2021-06-17
BR112021009106A2 (pt) 2021-08-10
EP3880675A1 (en) 2021-09-22
US20230035837A1 (en) 2023-02-02
IL282950A (en) 2021-06-30
WO2020099341A1 (en) 2020-05-22
CL2021001244A1 (es) 2021-11-19
PH12021551058A1 (en) 2021-11-22

Similar Documents

Publication Publication Date Title
PH12021500014A1 (en) Fused ring compounds
AU2017228405A8 (en) Small molecule IRE1-alpha inhibitors
PH12021551065A1 (en) Fused ring compounds
CA2999253C (en) Heterocyclic compounds and uses thereof
EP4282489A3 (en) Treatment of clostridium difficile infection
PH12020550051A1 (en) Glp-1 compositions and uses thereof
MX2023002507A (es) Inhibidores de cd73.
MY189454A (en) 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists
SG10201908839QA (en) 2,4-dihydroxy-nicotinamides as apj agonists
WO2017083431A3 (en) Hydroxypyridinone and hydroxypyrimidinone based compounds for treating bacterial infections
GEP20227406B (en) Chromane monobactam compounds for the treatment of bacterial infections
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
NZ788133A (en) Cd73 inhibitors
MX2020013630A (es) Analogos de rapamicina y usos de los mismos.
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
PH12021551058A1 (en) Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof
AU2018320416A8 (en) Pyridylpyridone compounds
EA201992370A1 (ru) Соединения и способы для лечения бактериальных инфекций
PH12019502277A1 (en) Crystalline forms of (s)-afoxolaner
WO2018211324A8 (en) Prodrugs for the treatment of disease
WO2019157225A3 (en) Certain chemical entities, compositions, and methods
EA202191343A1 (ru) Антибиотические соединения, способы их получения, фармацевтические композиции, содержащие их, и их применение
AU2018320419A1 (en) Morpholinylpyridone compounds
MX2020001808A (es) Nuevos compuestos.
WO2018096525A3 (en) Heteroaryl compounds and uses thereof